NATIONAL INSTITUTES OF HEALTH

Patients with high-risk, HR-positive, HER2-negative breast cancer showed better outcomes with anthracycline-plus-taxane chemotherapy vs. taxane-only regimens, according to a TAILORx trial analysis presented at SABCS 2024. T-AC regimens improved survival outcomes, particularly for patients with RS 31+ and tumors ≥2 cm. Anthracycline benefits increased with higher RS, but no trend was seen for RS 26-30. Long-term follow-up is needed due to potential late risks.

USC and Utah researchers received $2.7M from NIH to study retinitis pigmentosa, aiming to map retina's nerve connections at each disease stage to develop strategies for slowing vision loss.

John Miller cares for his wife Cheryl, who has Alzheimer's, navigating clinical trials and treatment setbacks. Despite challenges, John remains hopeful for future treatments and continues to seek options for Cheryl, emphasizing the emotional toll and daily struggles faced by caregivers.

Curative Biotechnology Inc. engages Golden Eagle Capital Advisors, Inc. as exclusive agent and strategic advisor. GECA, an international investment bank, offers comprehensive financial advisory solutions. Curative Biotech focuses on novel treatments for degenerative eye diseases, with a Metformin Reformulation targeting Age-Related Macular Degeneration in development.

Cooling devices may prevent hearing loss in cochlear implant patients and firefighters through temperature manipulation, according to University of Miami Miller School of Medicine researchers conducting NIH-funded clinical trials.

FDA experts call for more data on RSV vaccine safety in infants after Moderna trial pause. Panel seeks additional information before moving forward, emphasizing need for better understanding of immune response in different age groups.

TRACeR-I modeling involved global docking, high-resolution RifDock, and Rosetta sequence design. Combinatorial libraries were constructed, yeast-displayed, and screened. Binder proteins were expressed, purified, and characterized. CD, BLI, and peptide library methods were used. Recombinant MHC proteins were expressed, refolded, and biotinylated. Tetramer libraries were prepared, and peptide exchange validated. SSM scanning and sequence-based selection identified cross-reactive peptides. Immunogenicity assays, IFNγ ELISpot, flow cytometry, and bispecific-induced cytotoxicity assays were performed. X-ray crystallography determined the TRACeR–pMHC I complex structure. Sequence conservation analysis and structural modeling were conducted. Ethical approvals and reporting summary are included.